Senolytics to Improve Physical and Cognitive Function in Older Adults With Multiple Sclerosis
Ohio State University
Summary
This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.
Description
Multiple sclerosis (MS) is a chronic immune-mediated inflammatory and neurodegenerative disorder of the central nervous system (CNS), which afflicts approximately one million people in the United States. Age is the strongest driver of disease course in MS. With increasing age, most older adults with MS develop a progressive disease phenotype characterized by gradual accrual of irreversible neurological disability, for which there are no effective treatments that reliably slow disease progression. Cellular senescence is a hallmark of aging, whereby senescent cells accumulate with age and produc…
Eligibility
- Age range
- 50–85 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria 2. Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone. 3. Evidence of MS progression over the past 12 months. Exclusion Criteria: 1. Unstable coronary artery disease (myocardial infarction within 6 months or angina) 2. Hospitalization within 6 months 3. Stroke or transient ischemic attack in the past 6 months 4. Pulmonary arterial hypertension 5. Current or chronic history of liver disease 6. Alzheimer's or Parkinson's disease 7. Drug o…
Interventions
- DrugDasatinib and quercetin
Participants will receive 100 mg of dasatinib and 1250 mg of quercetin orally once a day for 2 days every 2 weeks over 12 consecutive weeks
Location
- Ohio State Martha Morehouse Outpatient CareColumbus, Ohio